Glaxo pipeline cure still in question

Glaxo’s ‘patent cliff’ has struck again.

Glaxo’s ‘patent cliff’ has struck again.

Glaxo progresses

The fourth quarter brought more progress for GlaxoSmithKline, the world no. 9 pharma by drug revenues, which is trying M&A to treat a chronic case of patent cliff. Glaxo shares erased losses from earlier on Wednesday, trading slightly higher after earnings were released. But the stock is now dithering. Investors are trying to make up their minds about how to react. Volumes and turnover rose year-on-year, lifting net profit to £1.22bn, above the £992m expected. New medicines helped, particularly Shingrix, a shingles vaccine, sales of which more than doubled to £221m. But the group also flagged a 5%-9% EPS drop in 2019. The forecast is pegged on a recently approved generic version of Advair, GSK’s best-selling drug, till recent years.

Costly cure

Part of GSK’s strategic blueprint for reducing development risk has also been aired in recent days with the tie-up with Germany’s Merck KGaA. The deal sees Glaxo acquire rights to a new-generation cancer immunotherapy. The cost is $4.2bn. Investors are aware that such outlays are necessities with pipelines maturing at alarming rates. But the market still winces on such news, including on Wednesday, when the group said that similar tie-ups “can be expected going forward”. These will eat up savings – seen at £500m a year – from splicing GSK’s consumer unit into Pfizer’s and spinning it off. Note the sharp negative reaction by Glaxo shares to the acquisition of Tesaro late last year.

Shares lag

Sure, GSK’s drive to tidy-up cash leeching developments continues.  Seven such projects were ended between Q2 and the end of the recent quarter. But market tolerance for capital intensive remedies remains in question. With GSK flagging continued generic risk ahead the stock is unlikely to embark on much progress for the year just yet. After a 12% advance in 2018, it has since lagged even a sluggish FTSE with a rise of 2.6%.

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.